-
Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY Vaccine (IF 5.5) Pub Date : 2024-03-12 Savanah Russ, Christopher Myers, Erin Licherdell, Acacia Bowden, Ellen Chinchilli, Runda Dahhan, Edwin Van Wijngaarden, Ian D. Plumb, Ghinwa Dumyati
Identify characteristics of healthcare personnel (HCP) who did not have timely initiation of the COVID-19 primary series, as well as HCP who did not receive a booster vaccine. Characteristics of HCP enrolled in a COVID-19 vaccine effectiveness study between 12/28/2020–12/01/2022 were compared by timing of receipt of 1st mRNA dose, and by receipt of a booster dose. Data for this retrospective cohort
-
Preparation and adjuvanticity against PCV2 of Viola philippica polysaccharide loaded in Chitosan-Gold nanoparticle Vaccine (IF 5.5) Pub Date : 2024-03-12 Ting Xu, Ancan Hong, Xueli Zhang, Yizhou Xu, Tao Wang, Qiang Zheng, Tiantian Wei, Qiuyue He, Zhe Ren, Tao Qin
The present Porcine circovirus type 2 virus (PCV) vaccine adjuvants suffer from numerous limitations, such as adverse effects, deficient cell-mediated immune responses, and inadequate antibody production. In this study, we explored the potential of a novel nanoparticle (CS-Au NPs) based on gold nanoparticles (Au NPs) and chitosan (CS) that modified polysaccharide (VPP) as efficient adjuvants for PCV
-
UK healthcare professionals’ attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration Vaccine (IF 5.5) Pub Date : 2024-03-12 Susan M. Sherman, Charlotte Allerton-Price, Nicola Lingley-Heath, Jasmine Lai, Helen Bedford
Varicella (chickenpox) is a highly contagious disease caused by the varicella-zoster virus. Although typically mild, varicella can cause complications leading to severe illness and even death. Safe and effective varicella vaccines are available. The Joint Committee on Vaccination and Immunisation has reviewed the evidence and recommended the introduction of varicella vaccine into the UK’s routine childhood
-
Influences of mpox disease perceptions, sources and contents of information exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex with men in Hong Kong, China Vaccine (IF 5.5) Pub Date : 2024-03-12 Doug H. Cheung, Siyu Chen, Yuan Fang, Fenghua Sun, Qingpeng Zhang, Fuk-yuen Yu, Phoenix K.H. Mo, Zixin Wang
Following the global mpox outbreak in 2022, multiple regions in Asia have been reporting ongoing mpox cases within high-risk groups, including gay, bisexual, and other men who have sex with men (GBMSM). An optimal level of vaccination rate is essential to prevent further mpox outbreaks. However, no existing studies have examined mpox vaccine uptake among GBMSM in East Asia. A cross-sectional survey
-
Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S. Vaccine (IF 5.5) Pub Date : 2024-03-11 Alice Shijia Yan, Neil Jay Sehgal
We undertook an observational study to assess the impact of state-level partisanship and parents’/guardians’ race/ethnicity on their degree of COVID-19 vaccine hesitancy. We observed a pooled cross-section of 59,280 U.S. adults residing with children in the same household between June 29 and November 14, 2022. Using household-weighted logistic regression models, we evaluated the association between
-
SimSAARlabim study – The role magic tricks play in reducing pain and stress in children Vaccine (IF 5.5) Pub Date : 2024-03-11 Jutta Teichfischer, Regine Weber, Elisabeth Kaiser, Martin Poryo, Julius Johannes Weise, Alexander Nisius, Sascha Meyer
Vaccination is an essential preventative medical intervention, but needle fearandinjection painmay result in vaccination hesistancy. To assess the role of magic tricks – no trick vs. one trick („disappearing handkerchief trick“) vs. three tricks (“disappearing handkerchief trick“, “jumping rubber band trick“, and “disappearing ring trick“) – performed by a professional magician and pediatrician during
-
An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice Vaccine (IF 5.5) Pub Date : 2024-03-11 Kota Senpuku, Chikako Kataoka-Nakamura, Yuta Kunishima, Toshiro Hirai, Yasuo Yoshioka
Enterovirus D68 (EV-D68), a pathogen that causes respiratory symptoms, mainly in children, has been implicated in acute flaccid myelitis, which is a poliomyelitis-like paralysis. Currently, there are no licensed vaccines or treatments for EV-D68 infections. Here, we investigated the optimal viral inactivation reagents, vaccine adjuvants, and route of vaccination in mice to optimize an inactivated whole-virion
-
Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 – December 2019 Vaccine (IF 5.5) Pub Date : 2024-03-11 Lore Merdrignac, Fatima Aït El Belghiti, Elisabetta Pandolfi, Lesly Acosta, Kateřina Fabiánová, Adele Habington, Manuel García Cenoz, Håkon Bøås, Julie Toubiana, Alberto E. Tozzi, Iolanda Jordan, Jana Zavadilová, Niam O'Sullivan, Ana Navascués, Elmira Flem, Ilena Croci, Mireia Jané, Pavla Křížová, Suzanne Cotter, Leticia Fernandino, Terese Bekkevold, Carmen Muñoz-Almagro, Sabrina Bacci, Piotr Kramarz
Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year. From December 2015 to December 2019, participating
-
Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System – United States, September 1, 2022 – March 31, 2023 Vaccine (IF 5.5) Pub Date : 2024-03-11 Pedro L. Moro, Grace Carlock, Nimita Fifadara, Tei Habenicht, Bicheng Zhang, Penelope Strid, Paige Marquez
Pregnant persons are at increased risk of severe COVID-19 illness. Bivalent mRNA COVID-19 vaccination is recommended for everyone, including pregnant persons. However, data are limited on the safety of bivalent mRNA COVID-19 vaccination during pregnancy. To evaluate and summarize reports to the Vaccine Adverse Event Reporting System (VAERS), a national spontaneous reporting system, among pregnant persons
-
Migration and infant immunization timeliness in New Zealand: Evidence from the Growing Up in New Zealand study Vaccine (IF 5.5) Pub Date : 2024-03-11 Ladan Hashemi, Maryam Ghasemi, Allen Bartley, John Fenaughty, Maryam Pirouzi, Cameron Grant
Migration has been recognized as an important determinant of child health outcomes including childhood vaccination status. This paper aims to examine the association between parental migration status and a less studied aspect of child immunization outcomes, namely timeliness, within the context of New Zealand (NZ), a country characterized by a substantial proportion of its resident population born
-
Pandemic antecedents – Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination Vaccine (IF 5.5) Pub Date : 2024-03-10 Monique Luisi, Mugur V. Geana, Jun Pei
A wealth of extant research focuses on identifying barriers to, and predictors of, COVID-19 vaccination. In addition to treating COVID-19 vaccination and related experiences as antecedents, this study analyzes the relationships between COVID-19 vaccination experiences and intent to receive the flu, shingles, and HPV vaccines. Analyses were performed on the responses from U.S. survey panel of 1,024
-
Vaccination during pregnancy and modulation of IgG response to pertussis vaccines in infants: The impact of different vaccine formulations Vaccine (IF 5.5) Pub Date : 2024-03-08 Nicholas Brousseau, Marie-Elen Angers-Goulet, Robin Bastien, Lingyun Ye, Manish Sadarangani, Scott A. Halperin
The IgG response following infant diphtheria-tetanus-acellular pertussis (DTaP) immunization is influenced by the formulation of the infant and/or the adult vaccine (Tdap) given during pregnancy. DTaP vaccines containing either 3 (DTaP3) or 5 (DTaP5) pertussis antigens are commonly used. By conducting a secondary analysis of a large randomized controlled trial, we compared IgG levels against pertussis
-
Virus-like particles of louping ill virus elicit potent neutralizing antibodies targeting multimers of viral envelope protein Vaccine (IF 5.5) Pub Date : 2024-03-08 Rapeepat Tandavanitj, Chayanee Setthapramote, Giuditta De Lorenzo, Ricardo Sanchez-Velazquez, Jordan J. Clark, Mara Rocchi, Colin McInnes, Alain Kohl, Arvind H. Patel
[Display omitted]
-
Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial Vaccine (IF 5.5) Pub Date : 2024-03-08 Yu-Wen Su, Yuan-Zheng Qiu, Yuan-Hui Wang, Yan Xu, Chao-Chao Huang, Qing Zhang, Chang Su, Jun-Heng Ma, Wen Liu, Yan Liu, Mao-Sheng Zhao, Han-Yu Yang, Chun-Lei Li, Xiang Lu
Continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants urges the development of new vaccines. We assessed the safety and immunogenicity of SYS6006.32, a bivalent vaccine (XBB.1.5/BQ.1), in healthy adults who had received SARS-CoV-2 primary vaccination. In a randomised, double-blinded, active-controlled trial, 200 participants were randomised to receive one dose
-
Current vaccine strategies and novel approaches to combatting Francisella infection Vaccine (IF 5.5) Pub Date : 2024-03-08 Jaikin E. Harrell, Chad J. Roy, John S. Gunn, James B. McLachlan
Tularemia is caused by subspecies of and can manifest in a variety of disease states, with the pneumonic presentation resulting in the greatest mortality. Despite decades of research, there are no approved vaccines against in the United States. Traditional vaccination strategies, such as live-attenuated or subunit vaccines, are not favorable due to inadequate protection or safety concerns. Because
-
Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial Vaccine (IF 5.5) Pub Date : 2024-03-08 Peter B. Gilbert, Youyi Fong, Nima S. Hejazi, Avi Kenny, Ying Huang, Marco Carone, David Benkeser, Dean Follmann
A central goal of vaccine research is to characterize and validate immune correlates of protection (CoPs). In addition to helping elucidate immunological mechanisms, a CoP can serve as a valid surrogate endpoint for an infectious disease clinical outcome and thus qualifies as a primary endpoint for vaccine authorization or approval without requiring resource-intensive randomized, controlled phase 3
-
Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice Vaccine (IF 5.5) Pub Date : 2024-03-08 Philippe St-Louis, Clément Martin, Vinay Khatri, Steve Bourgault, Denis Archambault
Intranasal administration of vaccines is an attractive delivery route to fight viral respiratory infections. However, there are only a few intranasal vaccines used in human, emphasizing the critical need to identify novel safe mucosal adjuvants and antigen delivery systems to expand their usage. We recently revealed an immunostimulating nanoparticle based on a fragment (R4R5) of the Curli-specific
-
Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1 Vaccine (IF 5.5) Pub Date : 2024-03-07 Ninaad Lasrado, Annika Rössler, Marjorie Rowe, Ai-ris Y. Collier, Dan H. Barouch
A new highly mutated Omicron subvariant BA.2.87.1 has recently been identified with over 30 amino acid mutations in the Spike protein compared with BA.2, BA.5, XBB.1.5, and JN.1 variants. Mutiple mutations in BA.2.87.1 are located in the N-terminal domain (NTD) rather than in the receptor binding domain (RBD) of the Spike protein. We evaluated neutralizing antibody (NAb) responses to BA.2.87.1 because
-
Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged ≥ 12 years, United States, August 2021-October 2022 Vaccine (IF 5.5) Pub Date : 2024-03-07 Lu Meng, LaTreace Harris, Lauren Shaw, Hoody Lymon, Hannah Reses, Jeneita Bell, Peng-Jun Lu, Lynn Gibbs-Scharf, Terence Chorba
COVID-19 booster dose vaccination has been crucial in ensuring protection against COVID-19 including recently predominant Omicron variants. Because vaccines against newer SARS-CoV- 2 variants are likely to be recommended in future, it will be valuable to understand past booster dose uptake among different demographic groups. Using U.S. vaccination data, this study examined intervals between primary
-
Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia Vaccine (IF 5.5) Pub Date : 2024-03-07 Ivette Maldonado, Nicolas Rodríguez Niño, Carlos F. Valencia, Daniela Ortiz, Nathalia Ayala, Liz D'silva, Santiago Castro Villarreal, Diego Salazar, Catalina Lozano, Daniela Angulo
Cervical cancer eradication is one of the main goals for 2030 by the World Health Organization, which can only be achieved with high vaccination rates against Human Papilloma Virus. In Colombia, more and better scientific evidence is required to increase confidence in vaccination. The objective of this study is to evaluate the safety profile of the quadrivalent vaccine against HPV in the risk of developing
-
A community-engaged approach to translate a Vaccine Hesitancy Scale into Haitian Creole Vaccine (IF 5.5) Pub Date : 2024-03-07 Greta Sirek, Sciaska Ulysse, Marie Jacques Toussaint, Chisa Nosamiefan, Ludwige Desrosiers, Mia Chandler, Rosalind Ramsey-Goldman, Dieufort J. Fleurissaint, Candace H. Feldman
Accurately translated health materials are needed to achieve equity in vaccine uptake among U.S. individuals with non-English language preferences. Verbatim translations may not capture the cultural and linguistic vernacular required to understand vaccine hesitancy. We leveraged a community-engaged approach to translate the Vaccine Hesitancy Scale (VHS) into Haitian Creole. Following the “WHO Guidelines
-
The Vaccine Training Barometer: Assessing healthcare providers’ confidence to answer vaccine-related questions and their training needs Vaccine (IF 5.5) Pub Date : 2024-03-07 Aurélie De Waele, Greet Hendrickx, Sara Valckx, Àngela Domínguez, Diana Toledo, Jesús Castilla, José Tuells, Pierre Van Damme
Healthcare providers (HCP) are seen by the public as the most trustworthy source of information about vaccination. While HCPs could be a valuable partner to increase vaccine confidence in general, it is not clear whether they feel confident themselves to address questions concerning vaccination. In the context of the EU Joint Action on Vaccination (EU-JAV), the Vaccine Training Barometer, an online
-
Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong Vaccine (IF 5.5) Pub Date : 2024-03-07 W.H.S. Wong, D.L. Leung, K.M. Yip, H.K. So, J.S. Rosa Duque, Y.L. Lau
The COVID-19 pandemic has affected people of all ages worldwide. However, there is still no information on the vaccine effectiveness (VE) of inactivated COVID-19 vaccines in children aged less than 3 years old. This study highlighted that 2 doses of CoronaVac were effective in preventing COVID-19, with a VE of 83.1 %.
-
PIRES2-EGFP/CTB-UreI vaccination activated a mixed Th1/Th2/Th17 immune system defense towards Helicobacter pylori infection in the BALB/c mice model Vaccine (IF 5.5) Pub Date : 2024-03-07 Sana Ghasemifar, Omid Chabak, Tohid Piri-Gharaghie, Abbas Doosti
The occurrence of gastritis, gastric ulcers, distal gastric cancer, and gastric mucosal lymphoma in humans is strongly associated with (). Vaccination is an effective preventive measure due to the increasing prevalence of antibiotic resistance. Fusion vaccination is a potentially practical approach. A fusion vaccine was created in this study by combining the toxin B subunit (CTB) with the antigenic
-
Investigation on the correlation factors of positive Streptococcus pneumoniae antibody and IgG antibody level of Streptococcus pneumoniae in the elderly over 60 years old in Shenzhen Vaccine (IF 5.5) Pub Date : 2024-03-07 Lixian Su, Xiaofeng Zhou, Weijun Peng, Jingwei Luo, Qiaoxiang Lin, Lizhen Liu, Jian Lin, Shufen Lin, Kechun Zhang, Hongbiao Chen, Muyun Liu
Pneumococcal Polysaccharide Vaccine (PPV-23), designed to protect against the most common serotype of Streptococcus pneumoniae, is intended to protect the elderly and other high-risk groups. However, the immunogenicity of all 23 pneumococcal polysaccharide vaccines in older adults has not been thoroughly studied. The purpose of this study is to look into the factors that influence the effect of the
-
Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong Vaccine (IF 5.5) Pub Date : 2024-03-05 Dongxuan Chen, Benjamin J. Cowling, Kylie E.C. Ainslie, Yun Lin, Jessica Y. Wong, Eric H.Y. Lau, Peng Wu, Joshua Nealon
The association between COVID-19 vaccination and length of hospital stay may provide further insight into vaccination benefits, but few studies have investigated such associations in detail. We aimed to investigate the association between COVID-19 vaccination and length of hospital stay in COVID-19 patients during Omicron waves in Hong Kong, and explore potential predictors. This retrospective cohort
-
A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice Vaccine (IF 5.5) Pub Date : 2024-03-04 Ashley C. Beavis, Krista Dienger-Stambaugh, Kelsey Briggs, Zhenhai Chen, Mathew Abraham, Paul Spearman, Biao He
Human immunodeficiency virus (HIV) infects and depletes CD4 T-cells, resulting in Acquired Immunodeficiency Syndrome (AIDS) and death. Despite numerous clinical trials, there is no licensed HIV vaccine. The HIV envelope glycoprotein (env) is a major target for vaccine development, especially for the development of antibody-mediated protection. In this study, we used J paramyxovirus (JPV) as a viral
-
Establishing priorities to strengthen National Immunization Technical Advisory Groups in Latin America and the Caribbean Vaccine (IF 5.5) Pub Date : 2024-03-03 Tracy Evans-Gilbert, J. Peter Figueroa, Pablo Bonvehí, Mario Melgar, Daniel Stecher, Renato Kfouri, Greta Munoz, Rakesh Bansie, Renato Valenzuela, Eduardo Verne, Daniel Salas, N. Jennifer Sanwogou
Following the COVID-19 pandemic, the Americas faced a significant decline in vaccination coverage as well as increased vaccine hesitancy. The objective of this paper is to summarize the challenges and opportunities outlined by the National Immunization Technical Advisory Groups (NITAGs) in Latin America and the Caribbean (LAC) and prioritize targeted interventions.
-
Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection Vaccine (IF 5.5) Pub Date : 2024-03-02 Xiaoxia Duan, Liangzhi Zhang, Ling Ding, Chaoyong Zhang, Zhenhua Chen, Yue Cheng, Xiao Wang, Hongxia Peng, Xueqin Tang, Xueling Ren, Juan Liao, Sufei Yang, Yu Zhu, Wei Luo, Yilan Zeng, Ping Yuan, Lu Long
Vaccination has been proven effective against infection with enterovirus A71 (EV-A71) in clinical trials, but vaccine effectiveness in real-world situations remains incompletely understood. Furthermore, it is not clear whether previous vaccination will result in symptom attenuation among post-vaccinated cases. Based on long-term data extracted from the only designed referral hospital for infectious
-
Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care Vaccine (IF 5.5) Pub Date : 2024-03-02 Sarah G. Yashar-Gershman, Alix T. Rosenberg, Muskaan Sawhney, Maria Fernanda Machicao, Howard R. Moskowitz, Henry H. Bernstein
Many children are still not vaccinated against COVID-19, often attributed to rising pediatric vaccine hesitancy. To address this complex public health issue, interventions that uncover parental thinking at point of care are needed to help facilitate discussions in the exam room. The cognitive science framework of Rule Developing Experimentation helps distinguish how people think about day-to-day topics
-
Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9–14 years of age: Interim analysis from a phase 3 clinical trial Vaccine (IF 5.5) Pub Date : 2024-03-01 Khalequ Zaman, Anne E Schuind, Samuel Adjei, Kalpana Antony, John J Aponte, Patrick BY Buabeng, Firdausi Qadri, Troy J Kemp, Lokman Hossain, Ligia A Pinto, Kristen Sukraw, Niranjan Bhat, Tsiri Agbenyega
World Health Organization human papillomavirus (HPV) vaccination recommendations include a single- or two-dose schedule in individuals 9–20 years old and advice for generating data on single-dose efficacy or immunobridging. The ongoing Phase 3 trial of Innovax’s bivalent (types 16 and 18) HPV vaccine (Cecolin®) assesses in low- and middle-income countries alternative dosing schedules and generates
-
Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic Vaccine (IF 5.5) Pub Date : 2024-02-29 Dana Meaney-Delman, Sarah Carroll, Kara Polen, Tara C. Jatlaoui, Sarah Meyer, Sara Oliver, Julianne Gee, Tom Shimabukuro, Hilda Razzaghi, Laura Riley, Romeo R. Galang, Van Tong, Suzanne Gilboa, Sascha Ellington, Amanda Cohn
As the worldwide COVID-19 pandemic unfolded, the clinical and public health community raced to understand SARS-CoV-2 infection and develop life-saving vaccines. Pregnant persons were disproportionately impacted, experiencing more severe illness and adverse pregnancy outcomes. And yet, when COVID-19 vaccines became available in late 2020, safety and efficacy data were not available to inform their use
-
An overview of the COVID-19 pediatric vaccine program – The U.S. experience vaccinating children ages 6 months through 17 years Vaccine (IF 5.5) Pub Date : 2024-02-29 Kevin Chatham-Stephens, Rosalind J. Carter, Chris Duggar, Kate R. Woodworth, Catherine Amanda Carnes, Achal Bhatt, Christina Ottis, Chris Voegeli, Shannon Stokley, Tara Vogt
COVID-19 vaccination decreases risk for COVID-19 illness and severe disease in children, including multisystem inflammatory syndrome (MIS-C) and death. On December 13, 2020, CDC recommended COVID-19 vaccination for persons ages ≥16 years, with expansion on May 12, 2021, to adolescents ages 12–15 years; to children ages 5–11 years on November 2, 2021; and to children ages 6 months–4 years on June 18
-
Protective efficacy of recombinant Toxoplasma gondii dense granule protein 15 against toxoplasmosis in C57BL/6 mice Vaccine (IF 5.5) Pub Date : 2024-02-29 Tanjila Hasan, Naomi Shimoda, Shu Nakamura, Barbara A. Fox, David J. Bzik, Nanako Ushio-Watanabe, Yoshifumi Nishikawa
is a pervasive protozoan parasite that is responsible for significant zoonoses. A wide array of vaccines using different effector molecules of have been studied worldwide to control toxoplasmosis. None of the existing vaccines are sufficiently effective to confer protective immunity. Among the different -derived effector molecules, dense granule protein 15 from the type II strain (GRA15 (II)) was recently
-
Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18–60 years: A double-blind, non-inferiority, randomized controlled trial Vaccine (IF 5.5) Pub Date : 2024-02-29 Davood Yadegarynia, Amirreza Keyvanfar, Hossein Keyvani, Shabnam Tehrani, Shahnaz Sali, Sara Abolghasemi
This study aimed to evaluate the non-inferiority of the FluGuard (a quadrivalent recombinant vaccine manufactured by Nivad Pharmed Salamat Company in Iran) by comparing its immunogenicity and safety with Vaxigrip Tetra (a quadrivalent inactivated vaccine manufactured by Sanofi Pasteur in France). In this double-blind, randomized controlled trial, eligible volunteers aged 18–60 were randomized to receive
-
Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9–14 in a metropolis area of China: Evidence for developing a vaccination strategy Vaccine (IF 5.5) Pub Date : 2024-02-29 Weiyu Zhou, Xiang Guo, Jia Lu, Xinyue Lu, Xiaoya Fu, Yihan Lu
Increasing countries are expanding the human papillomavirus (HPV) vaccination to men, which has not yet been licensed in China. This study investigated the parental willingness to accept (WTA) and pay (WTP) HPV vaccine for their sons aged 9–14. In Shanghai, a metropolis area of China, parents with boys aged 9–14 were recruited to complete an online questionnaire using a convenience sampling strategy
-
Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine Vaccine (IF 5.5) Pub Date : 2024-02-29 Michele Kohli, Michael Maschio, Amy Lee, Ataru Igarashi
The study objective was to estimate the incidence of COVID-19 infection, hospitalization, and deaths in Japan from September 2023 to August 2024 and potential impact of a monovalent XBB.1.5 variant–adapted Fall 2023 COVID-19 vaccine (modified version: XBB monovalent) for adults aged ≥18 years on these outcomes. A previously developed Susceptible-Exposed-Infected-Recovered model for the United States
-
Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan Vaccine (IF 5.5) Pub Date : 2024-02-27 Motoko Tanaka, Reiko Okubo, Shu-Ling Hoshi, Masahide Kondo
In Japan, the introduction of a fifth diphtheria–tetanus–acellular pertussis (DTaP) vaccination has been considered, and adolescents aged 11–12 years old who are currently receiving the diphtheria–tetanus (DT) vaccine are one candidate group. We analyze the cost-effectiveness of replacing the DT vaccine with the DTaP vaccine for 11-year-old adolescents and investigate the indirect effect of vaccinated
-
Region-wide assessment of National Immunization Technical Advisory Groups (NITAGs) using the NITAG Maturity Assessment Tool (NMAT) – Experience from the Eastern Mediterranean Region of the World Health Organization, 2023 Vaccine (IF 5.5) Pub Date : 2024-02-26 Gerald Etapelong Sume, Quamrul Hasan, Abigail Shefer, Louise Henaff, Kathleen F. Cavallaro, Catherine B. Tencza, Stephen C. Hadler, Ndiaye Sidy, Parwiz Sardar, Benjamin M. Kagina, Yvan Hutin
National Immunization Technical Advisory Groups (NITAGs) are independent bodies that help improve national immunization programmes in decision making on immunization policy. The new NITAG Maturity Assessment Tool (NMAT) provided an opportunity to conduct a region-wide assessment to improve NITAG capacity and foster institutional growth. We share experience of the Eastern Mediterranean Region (EMR)
-
Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018–2022 Vaccine (IF 5.5) Pub Date : 2024-02-26 Palwasha Anwari, Eleanor Burnett, Tyler P. Chavers, Akmal Samsor, Helah Safi, Najibullah Safi, Andrew D Clark, Umesh D. Parashar, Jacqueline E. Tate
In January 2018, Afghanistan introduced the monovalent oral rotavirus vaccine (Rotarix) nationwide, administered as a 2-dose series at six and ten weeks of age. We describe characteristics of intussusception cases and assess potential intussusception risk associated with Rotarix vaccination in Afghan infants. Multi-center prospective active hospital-based surveillance for intussusception was conducted
-
Neutralizing antibody titers against D8 genotype and persistence of measles humoral and cell-mediated immunity eight years after the first dose of measles, mumps, and rubella vaccine in Brazilian children Vaccine (IF 5.5) Pub Date : 2024-02-26 Letícia Kegele Lignani, Raquel de Vasconcellos Carvalhaes de Oliveira, Eliane Matos dos Santos, Luiz Antonio Bastos Camacho, Janaína Reis Xavier, Gloria Regina da Silva e Sá, Marilda Mendonça Siqueira, Andréa Marques Vieira da Silva, Juliana Gil Melgaço, Nathalia dos Santos Alves, Maria de Lourdes de Sousa Maia, Enirtes Caetano Prates Melo
Assess the level of measles vaccine-induced neutralizing antibodies against the D8 genotype and the persistence of humoral and cell-mediated immunity in children who received their first dose of the measles, mumps, and rubella vaccine eight years previously. Measles-specific IgG and neutralizing antibodies were determined in serum using ELISA and plaque reduction neutralization test, respectively.
-
Influenza vaccination in pregnant women in Iceland 2010–2020 and the burden of influenza in pregnant women and their infants Vaccine (IF 5.5) Pub Date : 2024-02-26 Iris Kristinsdottir, Asgeir Haraldsson, Valtyr Thors
Influenza vaccinations are recommended in pregnancy to protect both the pregnant woman and the unborn baby. The aim of this study was to assess the influenza vaccine uptake among pregnant women in Iceland in ten influenza seasons and to estimate the influenza disease burden on pregnant women and their infants. This was a retrospective, descriptive study on influenza vaccine uptake among pregnant women
-
Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model Vaccine (IF 5.5) Pub Date : 2024-02-26 Ariel Mundo Ortiz, Bouchra Nasri
The COVID-19 pandemic continues to be a worldwide public health concern. Although vaccines against this disease were rapidly developed, vaccination uptake has not been equal across all the segments of the population, particularly in the case of underrepresented groups. However, there are also differences in vaccination across geographical areas, which might be important to consider in the development
-
The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States Vaccine (IF 5.5) Pub Date : 2024-02-24 Anthony T. Newall, Allen L. Nazareno, David J. Muscatello, David Boettiger, Cécile Viboud, Lone Simonsen, Robin M. Turner
The influenza mortality burden has remained substantial in the United States (US) despite relatively high levels of influenza vaccine uptake. This has led to questions regarding the effectiveness of the program against this outcome, particularly in the elderly. The aim of this evaluation was to develop and explore a new approach to estimating the population-level effect of influenza vaccination uptake
-
Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023 Vaccine (IF 5.5) Pub Date : 2024-02-22 Caitriona Murphy, Mike Y.W. Kwan, Eunice L.Y. Chan, Joshua S.C. Wong, Sheena G. Sullivan, Malik Peiris, Benjamin J. Cowling, So-Lun Lee
A test negative study was carried out from 13 June through to 15 November 2023 enrolling 3183 children hospitalized with acute respiratory illness in Hong Kong. Influenza A and B viruses were detected in 528 (16.6%) children, among which 419 (79.4%) were influenza A(H3N2). The overall vaccine effectiveness against hospitalization associated with any influenza virus infection was estimated as 22.4%
-
Mortality risk after COVID-19 vaccination: A self-controlled case series study Vaccine (IF 5.5) Pub Date : 2024-02-22 Stanley Xu, Lina S. Sy, Vennis Hong, Paddy Farrington, Sungching C. Glenn, Denison S. Ryan, Abraelle M. Shirley, Bruno J. Lewin, Hung-Fu Tseng, Gabriela Vazquez-Benitez, Jason M. Glanz, Bruce Fireman, David L. McClure, Laura P. Hurley, Onchee Yu, Michael Wernecke, Ning Smith, Eric S. Weintraub, Lei Qian
Although previous studies found no-increased mortality risk after COVID-19 vaccination, residual confounding bias might have impacted the findings. Using a modified self-controlled case series (SCCS) design, we assessed the risk of non-COVID-19 mortality, all-cause mortality, and four cardiac-related death outcomes after primary series COVID-19 vaccination. We analyzed all deaths between December 14
-
Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017–2020 Vaccine (IF 5.5) Pub Date : 2024-02-22 Patricia C. Lloyd, Bradley Lufkin, Keran Moll, Rachel P. Ogilvie, Cheryl N. McMahill-Walraven, Daniel C. Beachler, Jeffrey A. Kelman, Xiangyu Shi, Shayan Hobbi, Kandace L. Amend, Djeneba Audrey Djibo, Shanlai Shangguan, Azadeh Shoaibi, Minya Sheng, Alex Secora, Cindy Ke Zhou, Lisa Kowarski, Yoganand Chillarige, Richard A. Forshee, Steven A. Anderson, Stella Muthuri, John D. Seeger, Annemarie Kline
Increased risk of thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector-based COVID-19 vaccinations has been identified in passive surveillance systems. TTS incidence rates (IRs) in the United States (U.S.) are needed to contextualize reports following COVID-19 vaccination. We estimated annual and monthly IRs of overall TTS, common site TTS, and unusual site TTS for adults aged
-
Audiovestibular adverse events following COVID-19 vaccinations Vaccine (IF 5.5) Pub Date : 2024-02-22 Aishwarya N. Shetty, Hannah J. Morgan, Linny K. Phuong, John Mallard, Diana Vlasenko, Christopher Pearce, Nigel W. Crawford, Jim P. Buttery, Hazel J. Clothier
Evidence regarding audiovestibular adverse events post COVID-19 vaccination to date has been inconclusive regarding a potential association. This study aimed to determine if there was an increase in audiovestibular events following COVID-19 vaccination in South-eastern Australia during January 2021–March 2023. A multi-data source approach was applied. First, a retrospective observational analysis of
-
Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age Vaccine (IF 5.5) Pub Date : 2024-02-22 Sanjeev M. Bijukchhe, Meeru Gurung, Bhishma Pokhrel, Mila Shakya, Dikshya Pant, Pratistha Maskey, Himang Maskey, Babita Dhakal, Shristy Rajkarkinar, Sabitri Bista, Merryn Voysey, Yama F. Mujadidi, Young Chan Kim, Rachel Atherton, Elizabeth Jones, Florence Mclean, Sonu Shrestha, Matilda Hill, Katherine Theiss Nyland, Sarah Kelly, Peter O'reilly, Ganesh Prasad Sah, Buddha Basnyat, Andrew J. Pollard,
Previously, the Vi-typhoid conjugate vaccine (Vi-TT) was found to be highly efficacious in Nepalese children under 16 years of age. We assessed the immunogenicity of Vi-TT at 9 and 12 months of age and response to a booster dose at 15 months of age. Infants were recruited at Patan Hospital, Kathmandu and received an initial dose of Vi-TT at 9 or 12 months of age with a booster dose at 15 months of
-
Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP Vaccine (IF 5.5) Pub Date : 2024-02-21 Jordan Plieskatt, Peter Bang, Grith Krøyer Wood, Mohammad Naghizadeh, Susheel K. Singh, Matthijs M. Jore, Michael Theisen
-
-
-
The immune response to a Coxiella burnetii vaccine in sheep varies according to their natural pre-exposure Vaccine (IF 5.5) Pub Date : 2024-02-21 Jens Böttcher, Benjamin U. Bauer, Christina Ambros, Michaela Alex, Ursula Domes, Sabine Roth, Kerstin Boll, Martin Korneli, Karl-Heinz Bogner, Andreas Randt, Britta Janowetz
-
Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18–24 Months: A phase Ⅳ clinical trial Vaccine (IF 5.5) Pub Date : 2024-02-21 Qiongzhou Yin, Yan Zheng, Zhifang Ying, Jingyu Li, Ya Jiang, Wenmei Bao, Youjian Dou, Yi Pu, Jin Lei, Haitao Yang, Ruiju Jiang, Yan Deng, Zhimei Zhao, Jing Pu, Jing Yang, Yadong Li, Min Xu, Wei Cai, Yanchun Che, Li Shi
-
The association between BCG scars and self-reported chronic diseases: A cross-sectional observational study within an RCT of Danish health care workers Vaccine (IF 5.5) Pub Date : 2024-02-19 William Leander Mæland Søvik, Anne Marie Rosendahl Madsen, Peter Aaby, Sebastian Nielsen, Christine Stabell Benn, Frederik Schaltz-Buchholzer
The live-attenuated vaccines (BCG) and have been associated with beneficial non-specific effects. We assessed the prevalence of BCG and vaccine scars in a cohort of Danish health care workers and investigated the association between the presence of vaccine scars and self-reported chronic diseases. Cross-sectional study utilizing baseline data collected during 2020–2021 at enrollment in a BCG trial
-
Liposomal co-encapsulation of a novel gemini lipopeptide and a CpG-ODN induces a strong Th1 response with the co-activation of a Th2/Th17 profile and high antibody levels Vaccine (IF 5.5) Pub Date : 2024-02-19 Ivana Gabriela Reidel, Cecilia Carol Curti, Léa Dorémus, Emile Béré, Adriana Delwail, Romina Cecilia Russi, Jean-Claude Lecron, Franck Morel, María Inés García, Diana María Müller, Jean-François Jégou, Carolina Melania Veaute
A successful vaccine depends on its capacity to elicit a protective immune response against the target pathogen. The adjuvant used plays an important role in enhancing and directing the immune response. Liposomes are vaccine adjuvants that allow the co-encapsulation of antigens and immunostimulants. Our aim was to evaluate the adjuvanticity of a cationic liposome (Lip) formulated with a novel lipopeptide
-
Hospitalizations of patients with herpes zoster in Poland during 2012–2021: A population-based study Vaccine (IF 5.5) Pub Date : 2024-02-17 Michał Rząd, Krzysztof Kanecki, Katarzyna Lewtak, Piotr Tyszko, Paweł Gorynski, Aneta Nitsch-Osuch
The varicella-zoster virus (VZV) is an infectious agent that causes both chickenpox and herpes zoster/shingles (HZ). This infection can take various clinical forms, result in permanent complications, and be a marker of immunosuppression, e.g. in the course of a neoplastic disease. Our study is a population-based, retrospective analysis of hospital discharge records of patients with HZ. Data were obtained
-
The intentions of French health university students to recommend and to receive the HPV vaccine are mainly influenced by vaccine knowledge, confidence in vaccines and personal HPV vaccination Vaccine (IF 5.5) Pub Date : 2024-02-17 Sébastien Bruel, Zohasina Rakotomampionona, Maxime Gignon, Nelly Agrinier, Ndeye Coumba Ndiaye, Christine Lasset, Bruno Giraudeau, Morgane Michel, Judith E. Mueller, Aurélie Gauchet, Anne-Sophie Banaszuk, Nathalie Thilly, Amandine Gagneux-Brunon
Despite documented effectiveness in preventing several cancers, genital warts and safety of Human Papillomavirus (HPV) vaccine, immunization coverage among French adolescents remains far from the 80 % target. University health students (HS) in France may promote HPV vaccine through a national service (Service Sanitaire des Etudiants en Santé). We aimed to evaluate intentions to recommend the HPV vaccine
-
2022 Polio outbreak, Rockland County, NY: Cost evaluation of strategies to prevent future outbreaks of vaccine-preventable diseases Vaccine (IF 5.5) Pub Date : 2024-02-16 Jamison Pike, James Lueken, Julie Zajac, Ashley Tippins, Shani Doss, Adina De Coteau, Chitra Punjabi, Maria Souto, Achal Bhatt
In 1994, the World Health Organization Region of the Americas was declared polio-free. In July 2022, a confirmed case of paralytic polio in an unvaccinated adult resident of Rockland County, New York was reported by the New York State Department of Health (NYSDOH) and Rockland County Department of Health (RCDOH). While only one case was identified, a single case of paralytic polio represents a public
-
Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018–2022: A secondary data analysis Vaccine (IF 5.5) Pub Date : 2024-02-16 Michael Rockson Adjei, Amos Longsignikuu, Ibrahim Saeed Iddris, Thomas Nang Suuri, Byrite Asamoah, Michael Okoye, Janet Vanessa Baafi, Chrysantus Kubio, Sally-Ann Ohene, Martin Peter Grobusch
Ghana witnessed an outbreak of measles in 2022 following the COVID-19 pandemic, and Savannah Region was among the regions severely impacted. The objective of this study was to conduct trend analysis of measles case incidence and measles-rubella (MR) vaccination coverage in the Savannah Region to identify gaps and propose remedial actions to mitigate future outbreaks of vaccine preventable diseases